

List of Review Article 2016-2017

2017

1. Lin L, Wu M, Zhao J. The initiation and effects of plasma contact activation: an overview. *Int. J. Hematol* 2017; 105:235-43.
2. Jahanban-Esfahlan R, Seidi K, Zarghami N. Tumor vascular infarction: prospects and challenges. *Int. J. Hematol* 2017; 105:244-56.
3. Atilla E, Atilla PA, Demirer T. Current treatment strategies in relapsed/refractory mantle cell lymphoma: where are we now? *Int. J. Hematol* 2017; 105:257-64.
4. Nomura S. Extracellular vesicles and blood diseases. *Int. J. Hematol* 2017; 105:392-405.
5. Sawada A, Inoue M, Kawa K. How we treat chronic active Epstein–Barr virus infection. *Int. J. Hematol* 2017; 105:405-18.
6. Sun Z, Lan X, Li S, Zhao H, Tang Z, Xi Y. Comparisons of argatroban to lepirudin and bivalirudin in the treatment of heparin-induced thrombocytopenia: a systematic review and meta-analysis. *Int. J. Hematol* 2017; online published on June 9, 10.1007/s12185-017-2271-8

2016

1. Ogawa Y, Ogura M, Tobinai K, Ando K, Suzuki T, Watanabe T, et al. A phase I study of vorinostat combined with bortezomib in Japanese patients with relapsed or refractory multiple myeloma. *Int. J. Hematol* 2016; 103:25-33.
2. Iba T, Thachil J. Present and future of anticoagulant therapy using antithrombin and thrombomodulin for sepsis-associated disseminated intravascular coagulation: a perspective from Japan. *Int. J. Hematol.* 2016; 103: 253-61.

3. Nagai S, Ozawa K. Regulatory approval pathways for anticancer drugs in Japan, the EU and the US. *Int. J. Hematol.* 2016; 104:73-84.
4. Maeda T. Regulation of hematopoietic development by ZBTB transcription factors. *Int. J. Hematol.* 2016; 104: 310-23.
5. Yasunaga S, Ohno Y, Shirasu N, Zhang B, Suzuki-Takedachi K, Ohtsubo M. Role of Geminin in cell fate determination of hematopoietic stem cells (HSCs). *Int. J. Hematol.* 2016; 104: 324-9.
6. Jiang Y, Chen Y, Huang R, Chen G. Comparison of the efficiency of ABVD versus BEACOPP for Hodgkin lymphoma treatment: a meta-analysis. *Int. J. Hematol.* 2016; 104: 413-9.
7. Mesa RA, Komrokji RS, Verstovsek S. Ruxolitinib dose management as a key to long-term treatment success. *Int. J. Hematol.* 2016; 104: 420-9.
8. Feng Y, Li X, Xiao J, Li W, Liu J, Zeng X, et al. ADAMTS13: more than a regulator of thrombosis. *Int. J. Hematol.* 2016; 104: 534-39.